FibroGen Inc (NASDAQ:FGEN)
| 10.86 Delayed Data As of Oct 22 |  +0.26 / +2.45%Today’s Change | 9.88 Today|||52-Week Range 57.21 | -70.72% Year-to-Date |
Latest FGEN News | Press Releases
| Can FibroGen (FGEN) Climb 136% to Reach the Level Wall Street Analysts Expect? Oct 21 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 10.60 |
| Today’s open | 10.42 |
| Day’s range | 10.34 - 10.86 |
| Volume | 27,043 |
| Average volume (3 months) | 1,409,267 |
| Market cap | $1.0B |
Data as of 3:59pm ET, 10/22/2021
Growth & Valuation
| Earnings growth (last year) | -137.10% |
| Earnings growth (this year) | -31.04% |
| Earnings growth (next 5 years) | -48.93% |
| Revenue growth (last year) | -31.28% |
| P/E ratio | NM |
| Price/Sales | 18.90 |
| Price/Book | 2.39 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| AVXLAnavex Life Sciences... | -0.15 | -0.83% |
| DBVTDBV Technologies SA | -0.06 | -1.08% |
| NOTVInotiv Inc | +0.42 | +1.26% |
| --Oxford BioMedica PLC | -0.10 | -0.54% |
Data as of 3:59pm ET, 10/22/2021
Financials
| Next reporting date | November 11, 2021 |
| EPS forecast (this quarter) | -$0.01 |
| Annual revenue (last year) | $176.3M |
| Annual profit (last year) | -$189.3M |
| Net profit margin | -107.36% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters San Francisco, California |
Forecasts
